251 related articles for article (PubMed ID: 16755205)
1. The obesity epidemic and its cardiovascular consequences.
Behn A; Ur E
Curr Opin Cardiol; 2006 Jul; 21(4):353-60. PubMed ID: 16755205
[TBL] [Abstract][Full Text] [Related]
2. [The "problem obesity": viewpoint of the internist].
Guagnano MT; Manigrasso MR; Capani F; Davì G
Ann Ital Chir; 2005; 76(5):407-11. PubMed ID: 16696212
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome treatment strategies.
Fujioka K
Pharmacotherapy; 2006 Dec; 26(12 Pt 2):222S-226S. PubMed ID: 17125449
[TBL] [Abstract][Full Text] [Related]
4. The progression of cardiovascular risk to cardiovascular disease.
Rosin BL
Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
[TBL] [Abstract][Full Text] [Related]
5. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
Madsbad S
Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
[TBL] [Abstract][Full Text] [Related]
6. Obesity and cardiovascular physiology: impact of some pharmacological agents.
Chaput JP; Bérubé-Parent S; Tremblay A
Curr Vasc Pharmacol; 2005 Apr; 3(2):185-93. PubMed ID: 15853638
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy to reduce visceral fat.
Blackburn GL; Waltman BA
Clin Cornerstone; 2005; 7(2-3):52-60. PubMed ID: 16473261
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease under the influence of excess visceral fat.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
[TBL] [Abstract][Full Text] [Related]
9. Challenges and strategies in managing cardiometabolic risk.
Repas TB
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S4-11. PubMed ID: 17784529
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options for modifying cardiometabolic risk factors.
Aronne LJ
Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
[TBL] [Abstract][Full Text] [Related]
11. Medical management of obesity.
Berke EM; Morden NE
Am Fam Physician; 2000 Jul; 62(2):419-26. PubMed ID: 10929704
[TBL] [Abstract][Full Text] [Related]
12. The link between abdominal obesity, metabolic syndrome and cardiovascular disease.
Ritchie SA; Connell JM
Nutr Metab Cardiovasc Dis; 2007 May; 17(4):319-26. PubMed ID: 17110092
[TBL] [Abstract][Full Text] [Related]
13. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Lee M; Aronne LJ
Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
[TBL] [Abstract][Full Text] [Related]
14. [Obesity and metabolic syndrome: clinical and therapeutic review].
Cuppini A; Matteini P
Monaldi Arch Chest Dis; 2005 Mar; 64(1):45-9. PubMed ID: 16128165
[TBL] [Abstract][Full Text] [Related]
15. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
Caterson ID; Finer N
Asia Pac J Clin Nutr; 2006; 15 Suppl():55-62. PubMed ID: 16928662
[TBL] [Abstract][Full Text] [Related]
16. Obesity, cardiovascular risk and pharmacotherapy.
Ruilope LM; Garcia-Robles R; Moreno B
Blood Press; 2002; 11(5):260-2. PubMed ID: 12458647
[No Abstract] [Full Text] [Related]
17. [Obesity in adults].
Suter PM; Kolyvanos NU; Käser L; Vetter W
Praxis (Bern 1994); 2007 Oct; 96(42):1617-24; quiz 1625-6. PubMed ID: 17974121
[No Abstract] [Full Text] [Related]
18. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
19. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
20. [Reducing obesity].
Letonturier P
Presse Med; 2006 Jan; 35(1 Pt 1):77-8. PubMed ID: 16470949
[No Abstract] [Full Text] [Related]
[Next] [New Search]
